Boost HIV Treatment with Enhanced Drug Bioavailability

Introduction

For individuals living with HIV, the effectiveness of antiretroviral therapy can be the difference between stable health and severe illness. The key to successful treatment lies not only in the development of potent antiviral drugs but also in ensuring these drugs are absorbed efficiently by the body. Our patented method enhances the bioavailability of HIV drugs, allowing them to be more effective at lower doses, improving patient outcomes and reducing side effects.

The Challenge of Drug Bioavailability

In HIV treatment, drug bioavailability—the proportion of a drug that enters the bloodstream and reaches its target—plays a critical role in the effectiveness of antiviral therapies. Many HIV drugs, while potent, struggle with low bioavailability, requiring higher doses to achieve the desired therapeutic effect. This can lead to unwanted side effects, increased costs, and reduced adherence to treatment.

For pharmaceutical companies, increasing the bioavailability of HIV drugs is essential for improving patient outcomes and ensuring the long-term success of treatment regimens. However, existing methods for improving bioavailability can be complex and expensive, limiting their practicality in large-scale drug production.

Why Choose Enhanced Drug Bioavailability for HIV?

Our patented method offers a highly effective solution to the issue of low bioavailability in HIV drugs. By utilizing advanced delivery mechanisms, this method increases the absorption of antiviral drugs in the body, ensuring that a higher percentage of the drug reaches its target cells. This leads to more consistent therapeutic results and reduces the need for higher doses, minimizing side effects and improving patient adherence.

For pharmaceutical companies, this technology offers a way to differentiate their HIV treatments by providing a superior product with enhanced efficacy. It is compatible with existing drug formulations, making it an adaptable solution that can be implemented with minimal disruption to current manufacturing processes. Moreover, the method is cost-effective, providing a competitive edge in both the commercial and clinical settings.

Key Benefits

Increased Drug Efficacy: Enhances bioavailability, allowing HIV drugs to be more effective at lower doses.
Reduced Side Effects: Minimizes the need for high doses, reducing the risk of adverse effects.
Improved Patient Adherence: Easier-to-manage doses encourage better compliance with treatment regimens.
Adaptable Technology: Compatible with existing drug formulations and manufacturing processes.

Elevate HIV Treatment with Enhanced Drug Bioavailability

Licensing this bioavailability-enhancing technology provides pharmaceutical companies with a groundbreaking tool to improve HIV therapies. By offering more efficient drug absorption, this method enhances treatment efficacy, improves patient outcomes, and sets a new standard for HIV care.

Please see terms and conditions

Abstract
Claims

Methods and compositions are provided for reducing transmission and/or infection of HIV in a subject by increasing the bioavailability of a drug in the subject. The methods and compositions provided herein include an efflux transporter inhibitor and a drug effective for reducing the transmission and/or infection of HIV in a subject. The efflux transporter inhibitor is effective to reduce the efflux of the drug through at least one of P-glycoprotein (Pgp), breast cancer resistant protein (BCRP), and multidrug resistant associated protein 1-9 (MRP1-9).

What is claimed is:

1. A method for increasing the bioavailability of an HIV drug in a subject, the method comprising the step of:

administering a therapeutically effective amount of a carrier, an HIV drug and an efflux transporter inhibitor to the subject, the efflux transporter inhibitor administered in an amount effective to reduce the efflux of the HIV drug through the subject’s T-cells as compared to using the same HIV drug in the same amount but without the efflux transporter inhibitor, wherein the HIV drug is Tenofovir and the efflux transporter inhibitor is selected from the group consisting of MK571, Pgp-4008, Fumitrimorgin C, and combinations thereof.

2. The method according to claim 1, wherein the HIV drug and efflux transporter inhibitor are topically applied together as a mucosal gel.

3. The method according to claim 1, wherein the efflux transporter inhibitor and HIV drug are administered at substantially the same time.

4. The method according to claim 1, wherein the efflux transporter inhibitor is administered in an amount of about 1 μM to about 1 mM.

5. The method according to claim 1, wherein a ratio of the efflux transporter inhibitor to the HIV drug is about 1:1 to about 1:100.

6. The method according to claim 1, wherein the efflux transporter inhibitor is administered in an amount effective to increase the bioavailability of the HIV drug by at least 50% as compared to using the same HIV drug in the same amount but without the efflux transporter inhibitor.

7. A composition for increasing the bioavailability of an HIV drug in a subject, the composition comprising:

a HIV drug;

an efflux transporter inhibitor; and

a carrier,

the efflux transporter inhibitor being present in an amount effective to reduce the efflux of the HIV drug in the subject’s T-cells as compared to using the same HIV drug in the same amount but without the efflux transporter inhibitor.

8. The composition according to claim 7, wherein composition is in the form of a mucosal gel.

9. The composition according to claim 7, wherein the efflux transporter inhibitor is in an amount of about 1 μM to about 1 mM.

10. The composition according to claim 7, wherein a ratio of the efflux transporter inhibitor to the HIV drug is about 1:1 to about 1:100.

11. The composition according to claim 7, wherein the efflux transporter inhibitor is in an amount effective to increase the bioavailability of the HIV drug by at least 50% as compared to using the same HIV drug in the same amount but without the efflux transporter inhibitor.

12. A method for increasing the bioavailability of an HIV drug in a subject, the method comprising the step of:

wherein the HIV drug and efflux transporter inhibitor are topically applied as a mucosal gel and the HIV drug is Tenofovir encapsulated in nanoparticles, and the efflux transporter inhibitor is selected from the group consisting of MK571, Pgp-4008, Fumitrimorgin C, and combinations thereof.

Title

Method of increasing the bioavailability of an HIV drug

Inventor(s)

Pradeep K. Karla

Assignee(s)

Howard University

Patent #

10201552

Patent Date

February 12, 2019